Acquired fructose intolerance

Summary

Acquired fructose intolerance (MONDO:0021759) is a disease and 3 clinical trials. Top therapeutic interventions include alanine. A subtype of disorder of fructose metabolism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired fructose intolerance
Mondo ID	MONDO:0021759
SNOMED CT	413427002
UMLS	C1531694
MedGen	288539
Is cancer (heuristic)	no

Also known as: acquired fructose intolerance · dietary fructose intolerance · fructose malabsorption · intestinal fructose intolerance

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inborn errors of metabolism › inborn carbohydrate metabolic disorder › disorder of fructose metabolism › acquired fructose intolerance

Related subtypes (2): hereditary fructose intolerance, essential fructosuria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00555191	PHASE2/PHASE3	COMPLETED	Fructose Malabsorption in Northern Norway
NCT00916487	Not specified	COMPLETED	Efficacy of Fructose Metabolizing Enzymatic Product in Fructose Malabsorption
NCT01288495	Not specified	TERMINATED	Randomized Control Trial of L-Alanine and Placebo in Fructose Intolerance

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALANINE	3	1